TargetMol

Nesolicaftor

Product Code:
 
TAR-T16681
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T16681-1mg1mg£148.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T16681-5mg5mg£252.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T16681-1mL1 mL * 10 mM (in DMSO)£270.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T16681-10mg10mg£389.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T16681-25mg25mg£621.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T16681-50mg50mg£854.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T16681-100mg100mg£1,131.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
PTI-428 specifically enhances cystic fibrosis transmembrane conductance regulator protein synthesis.
CAS:
1953130-87-4
Formula:
C18H18N4O4
Molecular Weight:
354.366
Pathway:
Membrane transporter/Ion channel; Autophagy
Purity:
0.9864
SMILES:
C[C@@H](O)c1nnc(o1)[C@H]1C[C@@H](C1)NC(=O)c1cc(no1)-c1ccccc1
Target:
CFTR; Autophagy

References

1. Mijnders M, et al. Correcting CFTR folding defects by small-molecule correctors to cure cystic fibrosis. Curr Opin Pharmacol. 2017 Jun;34:83-90.